Detalhe da pesquisa
1.
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Int J Cancer
; 151(8): 1345-1354, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603979
2.
Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
Cancer
; 127(13): 2262-2270, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764524
3.
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.
Cancer Chemother Pharmacol
; 92(3): 223-228, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439816
4.
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Eur J Cancer
; 149: 82-90, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33838392